Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. (NASDAQ: REVB) is a clinical-stage life sciences company developing Gemini, a proprietary PHAD®-based toll-like receptor 4 (TLR4) agonist designed to rebalance the innate immune response in acute and chronic inflammation-driven diseases. The REVB news feed on Stock Titan aggregates company press releases and related coverage so readers can follow key scientific, clinical, regulatory, and corporate developments.
News about Revelation Biosciences frequently highlights progress across its Gemini programs for acute kidney injury (GEMINI-AKI), chronic kidney disease (GEMINI-CKD), prevention of post-surgical infection (GEMINI-PSI), and treatment of severe burn-related hyperinflammation (GEM-PBI). Updates include clinical milestones such as Phase 1 and Phase 1b data from the PRIME study in stage 3 and 4 CKD patients, where the company has reported safety, reductions in inflammatory activity, and restoration of normal cellular responses to stimuli.
Investors and observers can also find announcements about interactions with the U.S. Food and Drug Administration, including submission and acceptance of an end-of-phase 1 meeting package for Gemini in AKI, as well as manufacturing news such as the start of GMP production of Gemini and placebo to support later-stage randomized, double-blinded, placebo-controlled trials.
Beyond clinical and regulatory updates, the REVB news stream covers financial and corporate actions disclosed by the company, including warrant exercise inducement transactions, special meetings of stockholders to approve share issuances under Nasdaq rules, and inducement equity grants under Nasdaq Listing Rule 5635(c)(4). Bookmark this page to monitor Revelation Biosciences’ ongoing disclosures about Gemini’s development, capital markets activity, and governance events.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Revelation Biosciences Inc. (NASDAQ: REVB) reported its year-end 2022 financial results, showcasing a significant cash increase to $5.3 million, up from $1.3 million in 2021, primarily from a $15.6 million public offering. The company plans to initiate a combined Phase 1a clinical study for REVTx-100 and REVTx-300 in the latter half of 2023, supported by positive preclinical data. Revelation's net loss for 2022 was $10.8 million, or $20.09 per share, an improvement from $12.0 million in 2021, indicating reduced operational expenses. The firm anticipates sufficient funds to support operations through June 2024.
Revelation Biosciences Inc. (NASDAQ: REVB) has appointed Dr. Julia Bohannon and Dr. Antonio Hernandez to its Scientific Advisory Board. Dr. Bohannon, an Associate Professor at Vanderbilt University Medical Center, specializes in immunomodulatory treatments for burn injuries. Dr. Hernandez, also from Vanderbilt, focuses on enhancing innate immunity and developing therapies for critical care patients. Both bring significant expertise and will guide the company's PHAD-based technology for preventing and treating healthcare-associated infections. CEO James Rolke expressed excitement about their contributions to Revelation's ongoing efforts in immunologic therapies.
org value="NASDAQ-NMS:REVB"Revelation Biosciences Inc. (NASDAQ: REVB), focused on immunologic-based therapies, announced that CEO James Rolke will join a fireside chat at the 35th Annual Roth Conference from March 12-14, 2023, in location value="LU/us.ca.laguel"Laguna Niguel, California. The chat is scheduled for March 14 at 12:30 p.m. PT in Healthcare - Salon 5. Attendees can access the live webcast via the org value="NASDAQ-NMS:REVB"Revelation website, with a replay available for 30 days. Mr. Rolke will also be available for one-on-one meetings.
Revelation Biosciences Inc. (NASDAQ: REVB) announced the closing of a public offering on February 13, 2023, raising approximately $15.6 million. The offering consisted of 2,888,600 common stock shares and 336,400 pre-funded warrants at $4.83 per share. Additionally, warrants to purchase up to 6,450,000 shares were included, with an exercise price of $5.36. The proceeds will fund clinical studies for REVTx-100 and REVTx-300, focusing on surgical site infections and acute kidney injury. The offering was made under registration statements declared effective on February 9, 2023, by the SEC.
Revelation Biosciences Inc. (NASDAQ: REVB) has announced a public offering of 3,225,000 shares priced at $4.83 each, along with warrants to purchase up to 6,450,000 additional shares at an exercise price of $5.36. The gross proceeds are expected to total approximately $15.6 million, intended for advancing the development of their therapies REVTx-100 and REVTx-300, including clinical trials and manufacturing. The offering is anticipated to close around February 13, 2023, pending usual conditions. Roth Capital Partners serves as the sole placement agent.